FibroGen, Inc. (FGEN) EPS Estimated At $-0.51; Straight Path Communications (STRP)’s Sentiment Is 1.28

April 17, 2018 - By William Brooks

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.51 EPS on May, 8.They anticipate $0.01 EPS change or 1.92% from last quarter’s $-0.52 EPS. After having $-0.27 EPS previously, FibroGen, Inc.’s analysts see 88.89% EPS growth. The stock increased 2.43% or $1.15 during the last trading session, reaching $48.55. About 174,510 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 78.19% since April 17, 2017 and is uptrending. It has outperformed by 66.64% the S&P500.

Straight Path Communications Inc (STRP) investors sentiment decreased to 1.28 in 2017 Q4. It’s down -0.45, from 1.73 in 2017Q3. The ratio has worsened, as 59 investment professionals started new and increased stock positions, while 46 sold and trimmed stakes in Straight Path Communications Inc. The investment professionals in our database now hold: 6.96 million shares, up from 6.64 million shares in 2017Q3. Also, the number of investment professionals holding Straight Path Communications Inc in top ten stock positions decreased from 9 to 7 for a decrease of 2. Sold All: 11 Reduced: 35 Increased: 43 New Position: 16.

Straight Path Communications Inc., together with its subsidiaries, holds, leases, and markets commercial fixed and mobile wireless spectrum licenses in the United States. The company has market cap of $2.34 billion. The firm holds 735 licenses of 39 gigahertz band; and 133 licenses in the local multipoint distribution service band. It currently has negative earnings. It offers point-to-point and point-to-multipoint wireless broadband digital telecommunications services.

The stock decreased 1.35% or $2.5 during the last trading session, reaching $183.37. About 1.83 million shares traded or 516.81% up from the average. Straight Path Communications Inc. (STRP) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 4 selling transactions for $4.68 million activity.

Havens Advisors Llc holds 9.58% of its portfolio in Straight Path Communications Inc. for 70,000 shares. Tig Advisors Llc owns 621,506 shares or 6.26% of their US portfolio. Moreover, Harvest Management Llc has 5.94% invested in the company for 49,467 shares. The New York-based Kellner Capital Llc has invested 3.77% in the stock. Water Island Capital Llc, a New York-based fund reported 313,903 shares.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 18 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 8 by Leerink Swann. Goldman Sachs downgraded the stock to “Neutral” rating in Friday, July 21 report. The firm earned “Buy” rating on Friday, December 4 by Citigroup. Credit Suisse upgraded FibroGen, Inc. (NASDAQ:FGEN) on Thursday, February 11 to “Outperform” rating. Mizuho initiated FibroGen, Inc. (NASDAQ:FGEN) rating on Wednesday, October 4. Mizuho has “Hold” rating and $61.0 target. The firm earned “Buy” rating on Tuesday, August 8 by Jefferies. The firm has “Buy” rating by Leerink Swann given on Wednesday, February 28. The firm has “Buy” rating given on Sunday, September 10 by Stifel Nicolaus. As per Wednesday, October 18, the company rating was maintained by Stifel Nicolaus. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Buy” rating by Jefferies on Monday, August 14.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.01 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 William Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: